Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Hexarelin Safe Side Effects: Comparison of Administration Protocols

Daily (no cycling) 40% of initial response Daily spikes (28–32 ng/mL peak) Cumulative. Resting HR increases 5–8 bpm by week 3 High. Significant by day 14 Poor for extended studies beyond 2 weeks 5 days on / 2 days off 85% of initial response Intermittent spike

This comparison does not assign a generated winner or score.

  • Daily (no cycling)
  • 40% of initial response
  • Daily spikes (28–32 ng/mL peak)
  • Cumulative. Resting HR increases 5–8 bpm by week 3
  • High. Significant by day 14
  • Poor for extended studies beyond 2 weeks
  • 5 days on / 2 days off
  • 85% of initial response
  • Intermittent spikes only on dosing days
  • Moderate. No cumulative baseline shift
  • Low. Minimal attenuation at 4 weeks
  • Strong for 4–8 week protocols
  • Alternate-day dosing
  • 70% of initial response
  • Reduced frequency (every 48 hours)
  • Low. Cardiovascular markers return to baseline between doses
  • Moderate. Some attenuation by week 6
  • Suitable for metabolic studies with longer timelines
  • Pulsed (2 weeks on / 2 weeks off)
  • 90% of initial response post-washout
  • Intermittent with full recovery periods
  • Minimal. Complete cardiovascular reset during off-weeks
  • Very low. Receptor sensitivity fully restored during washout
  • Ideal for studies requiring sustained efficacy across 12+ weeks
More references

Related material